Three-Parent IVF Meets Its Fine Print · Morning Gist
Wednesday, November 45 stories · 15 min
Three-Parent IVF Meets Its Fine Print
Gaps run through today's stories: three-parent IVF's promise versus early results, bone loss versus screening age, and state versus federal measles death counts.
Picked from 27 new articles across 12 sources · arrow keys for other days
Today in 30 seconds
30s left
Faulty maternal mitochondria returned in two of six tested children after three-parent IVF in unpublished Ukrainian data, one reaching 72%. story 1 ↓
Bone density falls fastest from a year before the final period to two years after, but routine US screening starts at 65. story 2 ↓
Flu deaths are running 60-80 a week against an expected peak near 1,800, and CDC's chief medical officer leaves after four months. story 3 ↓
Seventeen blood proteins tracked mortality risk in two older-adult cohorts, but the summary gives no effect sizes and cannot show causation. story 4 ↓
New York child dies of measles, the state's first such death in 30 years; Pennsylvania reports five, federal officials three nationwide. story 5 ↓
A Washington state resident died of bird flu complications after cattle exposure, the first such US death this year, the AP reports.
1/5STAT· Megan Molteni and Edward Chen· Nov 3
Faulty mitochondria can return after three-parent IVF, prompting doubts about its use
A mother's mitochondria can resurge in children after "three-parent IVF," small studies show. Some experts want it paused for preventing mitochondrial disease or tested first in infertility; others say it lowers risk but cannot guarantee prevention.
Why it matters · Families carrying mitochondrial mutations may hear this procedure described as prevention, when the evidence so far supports risk reduction, based on few children and little long-term follow-up.
Know this first
Context from the editor, not the article · 29 sec
1 · Mitochondrial DNA
Mitochondria, the structures that power cells, carry a small genome separate from the DNA in the cell nucleus. Children normally inherit it only from their mother, so her mutations can pass to them and cause severe, sometimes fatal, disease.
2 · Mixtures and thresholds
A cell holds many copies of mitochondrial DNA, and healthy and mutated copies can coexist. Symptoms depend on the proportion of faulty copies, so a child's percentage matters more than simply whether a mutation is present.
3 · Where it is allowed
2/5The Conversation: Health· Priya Bhardwaj, Senior Researcher in Orthopedic Surgery, Washington University in St. Louis· Nov 3
Bone loss speeds up around menopause, often before women know it
A bone researcher reviews the evidence: bone loss peaks silently around the final period. Screening, exercise, nutrition and hormone therapy can help, but the evidence varies, and the exercise trial did not establish fewer fractures.
Why it matters · Routine screening at 65 comes long after the fastest loss, so midlife women at higher risk may need to raise bone health with a clinician themselves.
Know this first
Context from the editor, not the article · 29 sec
1 · Density versus fractures
Bone density is a surrogate: it predicts fracture risk but is not the outcome patients care about. Treatments and exercise programs can raise density without any proof that they prevent broken bones, so the two results need separate evidence.
2 · How density is measured
A bone density scan, usually a DXA, a low-dose X-ray of the hip and spine, estimates mineral content in bone. Clinicians read it alongside age, medical history and other risk factors to judge fracture risk.
3 · Hormone therapy's contested history
3/5Your Local Epidemiologist· Katelyn Jetelina· Nov 3
Election-linked heart risks, an early flu season, and another CDC exit
Epidemiologist Katelyn Jetelina's Election Day roundup: two observational studies tie elections to more heart problems, early flu looks normal so far, and turmoil at the CDC makes her wary of federal vaccine-injury reporting.
Why it matters · It separates an alarming-looking flu curve from a real signal, and shows how falling trust in the CDC could weaken the system meant to catch rare vaccine harms.
Know this first
Context from the editor, not the article · 29 sec
1 · Observational studies and stress
Comparing heart events across time periods can reveal a link but cannot prove the cause. Seasons, infections and other changes may differ between periods. Stress is a plausible mechanism because it raises heart rate and blood pressure.
2 · How VAERS works
The Vaccine Adverse Event Reporting System collects reports of health problems after vaccination. Anyone can file one, and a report alone does not show the vaccine caused the problem. Its value lies in flagging unusual patterns for investigation.
3 · Upheaval at the CDC
The Centers for Disease Control and Prevention has had heavy staff losses and repeated leadership changes under Health Secretary Robert F. Kennedy Jr., a longtime vaccine critic. That is the backdrop to questions about trusting its data systems.
4/5Fight Aging!· Reason· Nov 3
Seventeen blood proteins track mortality risk in two older-adult cohorts
Researchers tested 4,265 blood proteins in 1,025 older adults and linked 17 to death from any cause over about eight years. The reported links replicated in a second cohort, but remain observational.
Why it matters · Blood protein panels are being promoted as aging measures and possible trial endpoints, so it matters which signals replicate and what they still cannot show.
Know this first
Context from the editor, not the article · 26 sec
1 · Proteomics in blood
Plasma, the liquid part of blood, carries proteins released or shed by tissues throughout the body. Proteomic platforms measure thousands at once, allowing researchers to search for levels that predict later disease or death.
2 · Proteomic aging clocks
An aging clock is a statistical model trained to estimate age from biological data. Organ clocks often use proteins linked to a particular organ. An estimate above someone's actual age is read as faster biological aging.
3 · Why clocks stay contested
Most clocks are built from associations seen in ordinary aging populations. Nobody has firmly established that shifting a clock's reading through treatment means a person will stay healthier or live longer.
5/5STAT· Associated Press· Nov 3
Child dies of measles in New York, the state's first such death in 30 years
A child in rural Lewis County has died of measles, New York's first measles death in 30 years, Gov. Hochul announced. US vaccination rates have fallen below the 95% needed to prevent outbreaks.
Why it matters · A childhood death from a vaccine-preventable disease shows the real-world cost of falling coverage, and the gap between state and federal counts means official national figures may understate deaths.
Know this first
Context from the editor, not the article · 26 sec
1 · Why measles spreads so easily
Measles is an airborne virus and among the most contagious known. One case can infect 12 to 18 others in a fully susceptible group, so outbreaks can start even when only a small share lack immunity.
2 · What the vaccine does
The measles, mumps and rubella (MMR) vaccine is about 97% effective after two doses. US children normally get the first dose at 12 to 15 months, leaving younger babies reliant on immunity around them.
3 · What measles can do
Most children recover, but measles can cause pneumonia and brain swelling. In US data, roughly 1 to 3 of every 1,000 infected children die, even with modern hospital care.
The U.K. licensed Newcastle University to perform the procedure in 2017 and reported eight births last year. Australia has also legalized it but has not started treating patients, and a 2015 congressional ban blocks it in the U.S.
Image: STAT
Scientists and ethicists are questioning whether "three-parent IVF" should be used first for the purpose it was designed for: preventing mitochondrial disease. STAT reports that U.K. results and small studies from clinics elsewhere show a mother's own mitochondria can resurface in children after the procedure. The doubts come as Australia prepares a national program.
How it works
Mitochondria, the cell's power plants, carry their own DNA, normally inherited from the mother. 1 (MRT) pair the parents' nuclear DNA with healthy mitochondria from a donor egg. 2 swaps nuclear DNA between a maternal and a donor embryo. 3 moves the mother's chromosomes into a donor egg before fertilization.
The problem: 4
A few maternal mitochondria can travel with the transferred material. Early lab work at Newcastle University, the only licensed U.K. clinic, put this below 2%. But in 2016, Shoukhrat Mitalipov's Oregon lab reported that a small remnant could take over as an embryo's cells divided. This "reversion" appeared in roughly 15% of cases. It now has been seen in children:
Greece, spindle transfer for infertility: 2 of 7 children, at 51% and 35% maternal mitochondria.
Newcastle, pronuclear transfer in mutation carriers: 3 of 8, at 5% to 16%, with no signs of disease.
Ukraine, pronuclear transfer for infertility (unpublished): 2 of 6 tested, at up to 12% and up to 72%. These mothers had no apparent disease-causing mutations, so the immediate concern is lower.
These samples are too small to give a reliable rate, and why reversion happens remains unresolved.
Does it still help?
Symptoms are expected once mutated mitochondria pass about 50%. Mary Herbert of Monash University, a former Newcastle leader, says Newcastle's data show a 75% to 100% reduction in transmission, with every child below that threshold. She says MRT should be described as reducing risk, not preventing disease. Her group is preparing to seek approval for an Australian trial that tracks whether levels stay stable as children grow.
Others go further. Embryologist Jacques Cohen wants a moratorium on disease-prevention use. Bioethicist Guido Pennings argues MRT should be developed only in controlled infertility trials, so children aren't exposed to known disease risk. Most people STAT interviewed wouldn't go that far, but support is growing for revisiting bans on infertility trials.
That is not an endorsement of current commercial use. A STAT investigation found clinics selling MRT to older women on scant evidence, and Maastricht's Bert Smeets doubts age-related infertility is a suitable target.
What's next
In Belgium, Ghent University's Dominic Stoop plans to treat seven patients per group, with first results hoped for next year. Regulators have approved two groups: people with a history of mitochondrial disease and those with 5, a set of hard-to-treat conditions in which eggs or embryos stop developing. Stoop calls the disease group "the most risky," since it faces any unknown risks plus the faulty mitochondria.
Some scientists and ethicists are now questioning whether preventing mitochondrial disease should be the first use of "three-parent IVF," the technique built for that purpose. STAT reports that U.K. results and small pilot studies at fertility clinics elsewhere show a mother's own mitochondria can resurface in children after the procedure, sometimes at high levels.
The doubts come as Australia, the second country to explicitly legalize the technique, prepares a national program. Last year's U.K. report of eight healthy children born to mothers carrying disease-causing mutations had raised hopes that countries such as the U.S., which bans the procedure, might eventually permit it.
"The general public may have the idea that it is very safe and low risk and that's just not the case," said Bert Smeets, a clinical genomics professor at Maastricht University. He sits on the committee that reviews patient applications at Newcastle University, the only licensed U.K. clinic.
Two ways to swap
The procedure, formally called mitochondrial replacement techniques (MRT), combines nuclear genes from a mother and father with mutation-free mitochondrial DNA from a donor egg. There are two main methods:
1, developed at Newcastle in the early 2000s, creates embryos from both the mother and the donor, then swaps the nuclear DNA of one for the other.
2, developed by Shoukhrat Mitalipov at Oregon Health & Science University, works before fertilization. It moves the mother's genetic material into a donor egg while her chromosomes are lined up in a structure called the spindle.
Neither method is perfectly clean, because a few maternal mitochondria can travel with the transferred material. Early results made this look manageable. Newcastle's 2010 lab data found less than 2% maternal mitochondria in reconstructed embryos, though many embryos did not survive the process. In 2009, Mitalipov's lab reported apparently healthy monkeys with no trace of mitochondrial DNA from the original eggs.
Why a tiny remnant matters
Human eggs behaved differently. Mitalipov's team could replace up to 99% of the defective mitochondria, but the few that clung to the spindle began to take over as the fertilized egg divided. Each generation of cells held fewer healthy mitochondria and more mutated ones.
An analogy may help: the remnant acts less like a fixed contaminant, which would stay at 1%, and more like a small population that can outgrow its neighbors.
The team rushed out a paper in November 2016, before understanding why or how this happened, and named the problem "3." The data suggested that in roughly 15% of cases, MRT could fail, letting fatal defects resurface or new health problems arise. The finding caused a stir, but Newcastle still won its license for pronuclear transfer in 2017. Ghent University bioethicist Guido Pennings's case for further research still treats reversion as a mystery to be solved.
Now seen in children
Blocked by the U.S. ban, Mitalipov turned to infertility. Three datasets now show reversion after birth:
Study
Method
Mothers
Children with reversion
Maternal mitochondria
Greece, published 2023
Spindle transfer
Under 40, repeated IVF failure
2 of 7
51% and 35%
Newcastle, published last year
Pronuclear transfer
Mutation carriers
3 of 8
5% to 16%
Nadiya Clinic, Ukraine, unpublished
Pronuclear transfer
Infertility treatment, no apparent disease mutations
2 of 6 tested
Up to 12% and up to 72%
These numbers are too small to establish a reliable rate, and the Ukrainian figures, shared with STAT, have not been published. The groups also differ in method and patients.
The Newcastle children show no signs of disease. In Ukraine, the mothers' mitochondria carried no apparent disease-causing mutations, so reversion there is less worrying in terms of known risks, said New York embryologist Jacques Cohen, who reviewed the data. The concern is what the same shift would mean in a carrier, where symptoms are expected above about 50% mutated mitochondria.
The case that it still works
Mary Herbert, a former Newcastle leader now at Monash University in Melbourne, says Newcastle's clinical data show a 75% to 100% reduction in transmission of disease-causing mutations, with levels below the 50% threshold even where reversion occurred. She adds that "we have known for a decade that MRT may not work in all cases." In her view, it should be described as reducing risk, not "as a means of preventing" disease.
Her group is training embryologists and preparing to ask the Australian government to approve a trial in women carrying mutations. It would track any carried-over mutated DNA "to ensure that levels remain stable over time and across different organ systems." That stability has not yet been shown: the oldest evidence here comes from young children.
A second, less certain risk
MRT also pairs a mother's nuclear DNA with a stranger's mitochondrial DNA, a combination that does not normally occur. Some mouse research suggests the mismatch could cause immune or other problems, and mice carrying mitochondrial DNA from two animals have shown behavioral and cognitive abnormalities. This evidence comes from animals; the article reports no such effect in children.
A spectrum of positions
Pause: Cohen wants a moratorium on MRT for disease prevention until reversion can be minimized, while following the children already born. "The field is showing that it's a bad idea," he said.
Infertility only: Pennings argues MRT should be developed only in controlled trials for infertile couples, so researchers can study reversion without exposing children to known disease risk. Most people STAT interviewed would not go that far.
Open infertility trials: Esther Braun, a Ruhr University ethicist, argued in 2024 for changing U.K. and Australian law to allow them, saying earlier assessments may have underestimated both MRT's risks and the suffering of involuntary childlessness. She rejects routine commercial use until trials show it works.
That distinction matters because clinics are already selling MRT. A STAT investigation published Monday found IVF clinics worldwide pitching it to older women on scant evidence. In March, a Smeets-led group proposed a staged path: define the infertility types MRT might plausibly address, study them in the lab, then run small pilots only in those patients. Smeets doubts age-related infertility qualifies.
What happens next
Ghent University is testing something close to that model. Fertility specialist Dominic Stoop and geneticist Björn Heindryckx have studied 4, or oocyte/zygote/embryo maturation arrest, a group of hard-to-treat infertility conditions. Their unpublished analysis of tens of thousands of IVF cycles suggests it occurs about equally across ages.
Stoop plans to start with seven patients in each of three groups: mitochondrial disease history, OZEMA and advanced maternal age. Belgian regulators have approved the first two, and he hopes for first results next year. The third group awaits more 5 data. Any unknown risk would affect all three groups, he argues, while disease carriers also face the risk of abnormal mitochondria, making them "the most risky group."
Britain's 6 says its scientific committee has considered the infertility research, but only people at very high risk of passing on serious mitochondrial disease remain eligible.
The article leaves key questions open: why reversion happens, which embryos it will affect, and whether levels climb as children grow. It also does not weigh MRT against alternatives such as embryo screening or donor eggs.
Remember
Carryover of under 2% in early lab embryos did not predict outcomes: some children later measured far higher.
The worrying 51% and 72% readings came from infertility patients; the disease carriers' children stayed at 16% or below.
Ethicists now debate an unusual inversion: whether infertile patients, not disease carriers, are the safer first group for trials.
The Women's Health Initiative trial, reported in 2002, linked combined hormone therapy to higher breast cancer, stroke and clot risks, and use fell sharply. Later analyses suggested a better balance for younger women closer to menopause.
Infographic showing bone's internal framework thinning from normal to severe osteoporosis, alongside stooped posture from spinal fractures.
Priya Bhardwaj, a skeletal biology researcher at Washington University School of Medicine in St. Louis, argues that menopause is the time to start talking about bones. Her article is an evidence overview, not a new study, and it gives few effect sizes.
Why the timing is awkward
Bone constantly renews itself through 1: cells called 2 remove old bone and 3 build its replacement. Estrogen helps regulate this. As estrogen falls, removal can outpace replacement, leading toward 4, in which bones become porous and fragile. There are often no symptoms until a fracture.
The 5, a long-term US study of midlife women, tracked bone density in 862 participants. On average, loss at the lower spine and near the hip was fastest from about one year before the final period to two years after, then slowed without stopping.
Menopause is confirmed only after 12 straight months without a period. By then, about two of those three fast years have passed. These are averages from density measurements, and individual women vary. They do not show who will fracture.
What the evidence supports
Screening. The 6, an independent expert panel, recommends scans for women 65 and older, and for younger postmenopausal women at higher fracture risk. Risk factors include low body weight, smoking, excessive alcohol use and a parent's hip fracture. A UK trial of more than 12,000 women aged 70 to 85 paired screening with treatment recommendations for those at high risk. Hip fractures fell over five years, but osteoporosis-related fractures overall showed no statistically significant reduction. The trial says nothing about when screening should begin.
Exercise. A 2018 Australian trial tested supervised heavy resistance and impact training in postmenopausal women with low bone mass. After eight months, they did better on bone density and physical function than women on a less intensive home program. The women were carefully screened and closely supervised, and the trial did not establish fewer fractures. People with osteoporosis or earlier fractures may need guidance on safe loads.
Nutrition. Calcium and vitamin D support bone. Supplements may help when intake is low or a deficiency needs treatment, but they do not replace osteoporosis medicines.
Hormone therapy.7, which delivers hormones throughout the body, relieves hot flashes and helps prevent bone loss and fractures. Bhardwaj says the balance is generally favorable for women under 60 or within 10 years of menopause onset who have no medical reason to avoid it. The article doesn't quantify those benefits or risks.
Other causes and open questions
Bone loss isn't always down to menopause. In 8, overactive glands in the neck produce excess parathyroid hormone, which can weaken bones, and finding it can change care. Whether screening earlier in the transition prevents fractures remains unanswered here.
Priya Bhardwaj, a skeletal biology researcher at Washington University School of Medicine in St. Louis, argues that the menopausal transition is the right moment to bring up bone health, while a woman still feels well. Her article is an overview of existing evidence rather than a new study. It is careful about what each piece of evidence shows, but it reports few effect sizes, so the strength of several claims can't be judged from the article alone.
The problem: loss with no warning
Bone is living tissue that renews itself through 1. Cells called 2 remove old bone, and cells called 3 build its replacement. As an analogy, think of a demolition crew and a building crew working on the same structure, with estrogen helping to coordinate them. When estrogen declines around menopause, demolition can outpace rebuilding. The result can be bone loss and eventually 4, a condition in which bones become porous and fragile.
Osteoporosis often causes no noticeable symptoms until a bone breaks. It can affect men and younger people too, though it becomes more common with age. Spinal fractures can cause height loss and a stooped posture.
Why the timing makes it hard to catch
The main timing evidence comes from the 5, a long-term US study of women in midlife. An analysis of 862 participants tracked bone density relative to each woman's final menstrual period. On average, loss at the lower spine and near the hip was fastest from about one year before that period until two years after it. Loss then slowed but did not stop.
The difficulty is that natural menopause is confirmed only after 12 consecutive months without a period and with no other explanation. An illustrative timeline: a woman has her last period in March 2026. Her fastest loss would, on the average pattern, run from about March 2025 to March 2028. She couldn't confirm menopause until March 2027, when about two of those three years had passed.
Bhardwaj cautions that these findings do not mean every woman loses the same amount of bone or develops osteoporosis. This study measured density over time, not fractures, and its results are averages from following women rather than testing an intervention. It supports paying attention during the transition, but doesn't by itself show that acting then prevents broken bones.
Screening: useful, but not at menopause for everyone
To estimate fracture risk, clinicians consider low body weight, smoking, excessive alcohol use and whether a parent broke a hip. A bone density scan measures bone mineral density and adds to that picture.
The 6, an independent panel of preventive-care experts, recommends screening women 65 and older. It also recommends screening younger postmenopausal women when their history and risk factors point to a higher chance of fracture. Bhardwaj stresses that this doesn't mean every woman needs a scan as soon as her periods change. These rules cover routine screening only. Anyone with known osteoporosis, a fracture after a minor fall, or a disease or medicine that causes bone loss needs individual evaluation.
The trial evidence she cites comes from older women. In a UK trial, more than 12,000 women aged 70 to 85 received either usual care or screening followed by treatment recommendations for those at high risk. Over five years, the screening group was less likely to break a hip. When osteoporosis-related fractures at different sites were analyzed together, the reduction was not statistically significant. The article doesn't give the size of the hip benefit. The trial supports screening linked to treatment in older women, but it can't say when screening should begin during the menopausal transition.
Exercise: better density, unproven for fractures
Bones respond to force. Walking and stair climbing make them carry body weight, while resistance exercise adds force as muscles pull on bone. Balance training, such as tai chi, targets stability and falls, a separate route to a fracture.
An Australian trial published in 2018 tested supervised heavy resistance and impact training in postmenopausal women with low bone mass. After eight months, participants did better than those on a less intensive home program, on bone density and physical function. There are three limits. The women were carefully screened, the training was closely supervised, and the trial did not establish a reduction in fractures. People with osteoporosis, prior fractures or physical limitations may need guidance on movements and loads.
Nutrition: necessary, not a substitute
Calcium supplies mineral that gives bone its strength, and vitamin D helps the body absorb it. Adequate protein is part of a balanced diet. Food sources of calcium include dairy, fortified alternatives, canned sardines or salmon with edible bones, bok choy and broccoli. Supplements may help when intake is too low or a deficiency needs treatment, but they don't replace osteoporosis medicines when those are needed. The article cites no trial data for this section.
Treatment: hormones and other drugs
7, which delivers hormones throughout the body, can relieve hot flashes and night sweats and help prevent bone loss and fractures. Bhardwaj writes that for women younger than 60 or within 10 years of menopause onset, with no medical reason to avoid it, the balance of benefit and risk is generally favorable for troublesome symptoms and preventing bone loss. That balance varies with age, time since menopause, medical history and the specific treatment, so she advises revisiting the decision over time. The article doesn't list or quantify the risks.
Other osteoporosis medicines either slow bone breakdown or stimulate formation. The article doesn't name them or compare them.
Menopause may also be only part of the explanation. Hormonal disorders, digestive conditions and long-term 8 treatment (steroid medicines) can all weaken bone. In 9, one or more parathyroid glands in the neck make too much parathyroid hormone, which can raise blood calcium and weaken bones. Identifying it can change the care plan, which is why Bhardwaj argues for investigating the cause of bone loss rather than attributing it to aging.
Access and what remains open
Advice about scans assumes people can get them. A 2025 audit of 22 Asia-Pacific countries and regions, covering osteoporosis broadly rather than menopause specifically, found scan waits ranging from the same day to nearly a year. Gaps in medicine coverage also limited affordability.
The central question stays open: the article offers no trial showing that assessing or treating women during the transition itself, rather than later, reduces fractures. Bhardwaj's case rests on the biology, the timing data and evidence from other groups.
Remember
Bone density gains from exercise are not proof of fewer fractures; the Australian trial did not establish that.
The UK screening trial found fewer hip fractures, but no significant drop across osteoporosis-related fractures overall, and only in women 70 to 85.
Unexplained bone loss deserves investigation: conditions like primary hyperparathyroidism or long-term steroid use may be the cause, not menopause alone.
Daily atrial fibrillation burden in North Carolina device patients, comparing summer 2016 with the election window.1 / 3
On US midterm Election Day, epidemiologist Katelyn Jetelina's newsletter, Your Local Epidemiologist, covered heart risks, an early flu season, CDC turmoil, and a mother's dilemma over reporting a vaccine reaction.
Elections and heart problems
Two studies link elections with more cardiac trouble. One compared heart-device records from 2,436 North Carolina patients in a six-week window around the 2016 election with a summer window. Abnormal heart rhythms ran 77% higher around the election.
The other followed 6.4 million 1 members in California in 2020. Cardiovascular hospitalizations rose 17% in the five days after the vote, 666 versus 569 two weeks earlier. Heart attack hospitalization rates rose 42%.
Stress is the suspected mechanism, but neither study proved it. By my arithmetic, the California gap is about 1.5 admissions per 100,000 people. Summer-to-autumn differences and the pandemic could also muddy these comparisons.
Flu is early, not obviously worse
Every US region now has a flu 2 above 3%, meaning more than 3% of tests come back positive, which Jetelina treats as the start of flu season. About 60-80 people are dying each week, and she expects about 1,800 a week at the peak.
She sees no red flags yet. Hospitalizations are climbing at the expected rate, Europe also started early, and the CDC's forecasters expect a season like last winter. All 116 virus samples tested in Canada matched this year's vaccine strains, though that is a small, early sample and doesn't measure protection. She advises getting a flu shot now.
Another CDC exit
Dr. Jennifer Shuford is leaving as deputy director and chief medical officer of the Centers for Disease Control and Prevention (CDC) after four months. She cites family reasons. Jetelina, who says she is among the more than one in three staff who have left or been fired in 18 months, argues the exit shows scientists can't outweigh the agency's political appointees. That is her interpretation, not something the article documents.
Should a parent report a vaccine reaction?
A mother whose three-year-old recovered from a rare flu shot reaction asked whether to trust 3, the Vaccine Adverse Event Reporting System, with his data. The article doesn't name the reaction. VAERS relies on voluntary reports to catch rare safety signals, so lost trust means missed signals.
Jetelina says VAERS has not been tampered with, but she worries a report could be ignored, used to inflate risk, or misused. She leans toward reporting to the manufacturer, which must legally forward cases to VAERS while keeping the original records itself. She cites no actual misuse, so this is precaution rather than evidence. She also stresses that such reactions are far rarer than the vaccine's benefits.
Also noted
An mRNA peanut allergy treatment has entered its first human trial, with 32 adults. A deal cuts the 4 malaria vaccine's price by about 40%, which could cover up to one million more children.
On the day of the US midterm elections, Katelyn Jetelina, the epidemiologist behind the newsletter Your Local Epidemiologist, published a roundup with four main threads: evidence linking elections to heart problems, an early flu season, another senior departure from the Centers for Disease Control and Prevention (CDC), and a mother's question about whether to report her son's vaccine reaction to the government. Much of it is judgment rather than new data, and the distinction matters.
Elections and the heart
Jetelina cites two studies, both highlighted by STAT News.
The first used heart-device records from 2,436 patients in North Carolina. Researchers compared a six-week window around the 2016 presidential election (October 25 to December 6) with a summer window (June 1 to July 12). The rate of abnormal heart rhythms was 77% higher in the election window. The study's chart tracks 1 burden, a measure of how much a person's heart is in atrial fibrillation, a common irregular rhythm.
The second followed 6.4 million adult 2 members in California around the 2020 election. Cardiovascular hospitalizations rose 17% in the five days after the vote: 666 admissions, against 569 on the same weekdays two weeks earlier. Heart attack hospitalization rates rose 42%.
The proposed mechanism is stress. Attack ads and uncertainty can trigger the fight-or-flight response, which raises heart rate and blood pressure. But Jetelina is clear that neither study proved election stress caused the increases.
Some context the article doesn't provide helps in weighing these numbers. These limits are my reading, not the article's:
The absolute change is small. The California gap is 97 admissions across 6.4 million people, or roughly 1.5 per 100,000 over five days.
The comparison periods differ. Summer and late autumn can differ in infections, weather and routine, so the North Carolina comparison may capture more than politics. The 2020 window also fell during the COVID-19 pandemic.
The patients are specific. People with implanted heart devices already have heart disease, so the 77% figure may not apply to the general population.
Jetelina's advice is modest: walk, do yoga, spend time with supportive people, and go to the hospital if something feels wrong, even if tests may come back normal. None of the studies tested those coping measures.
Flu: early, but so far ordinary
Flu began unusually early this season and started in the West. Every US region now has a 3 above 3%, meaning more than 3% of flu tests are coming back positive, which Jetelina treats as the marker of flu season. Hospitalizations lag infections, because severe illness takes time to develop, and are now rising exponentially. About 60-80 people are dying of flu each week. She expects that to reach about 1,800 a week at the peak, more than 20 times the current level.
That looks alarming, but she gives four reasons it may mostly reflect timing:
Shape of the curve. Hospitalizations are rising at about the expected rate; the curve has simply started sooner.
International pattern. The UK and other parts of Europe also started early, and the Southern Hemisphere had a fairly typical season. That hemisphere is a decent but imperfect preview of the Northern winter.
Official forecast. The CDC's 4 expects a season similar to last winter.
Vaccine match. All 116 flu virus samples tested in Canada matched the strains in this year's vaccine.
That last point is early and limited. It comes from one country and a small sample, and a strain match in the lab is not the same as measured protection. Jetelina says this could all change, but for now she sees no red flags, and she recommends getting a flu shot now.
Another CDC departure
Dr. Jennifer Shuford is leaving her post as CDC deputy director and chief medical officer after four months. A former Texas health commissioner, she managed the West Texas measles response and worked with Kennedy during it. Jetelina alludes to the "Vitamin A fiasco" from that outbreak, when Kennedy's promotion of vitamin A for measles drew criticism from doctors.
Shuford joins a list that includes Susan Monarez, fired after less than a month as director; Dave Weldon, whose nomination was pulled before his hearing; two acting directors in under a year; the previous chief medical officer; and several center directors. More than one in three CDC staff have left or been fired in the past 18 months, according to Jetelina, who says she is among them.
Shuford cites family reasons. Jetelina argues the exit nonetheless shows that even skilled scientists can't outweigh the political appointees embedded in the agency. That is her interpretation, from someone with a personal stake and an openly critical view of the administration. The article offers no direct evidence connecting Shuford's exit to those appointees.
A vaccine reaction and a question of trust
A reader who works in public health wrote that her three-year-old had a rare reaction to a flu shot. He recovered, and she wants the reaction studied. Her question was whether she could trust 5, the Vaccine Adverse Event Reporting System, with his data. The article doesn't say what the reaction was.
VAERS is a 6 system: it depends on people choosing to report rather than actively tracking everyone vaccinated. Each report that goes unfiled is a potential blind spot. If parents stop reporting, Jetelina warns, a real safety problem could go unnoticed until many more children are affected. A chart in the article shows such events are far less common than the benefits of flu vaccination.
She gave the mother two options:
Report to the manufacturer. Companies follow up on every report through their 7 systems, the processes for tracking drug safety. They must by law pass reports to VAERS, so the case is still counted, but the company holds the original medical files and contact details.
Report directly to VAERS. Jetelina says it remains legitimate and has not been tampered with. But VAERS typically obtains medical records, and she sees two risks: the case could be ignored or used to inflate risk, and the data could be misused.
She leans toward the manufacturer route, and says it hurts to do so. This is a precaution based on distrust of the administration; she cites no instance of VAERS data being misused. Colleagues helped shape the guidance, but it remains expert opinion, not a finding.
Smaller positive news
Peanut allergy. An mRNA treatment designed to retrain the immune system to tolerate peanuts is in a first human trial, a 8 study testing safety and early signs of effect. It is enrolling 32 allergic adults in Australia and New Zealand, with results expected in early 2027.
Remember
A 17% relative rise in hospitalizations was only 97 extra admissions among 6.4 million people, so check absolute numbers.
An early flu season is not automatically a severe one; the curve's shape and forecasts currently point to an ordinary winter.
Voluntary safety systems depend on trust: if parents stop reporting, rare vaccine harms may take longer to detect.
Researchers tested 4,265 proteins in the blood 1 of 1,025 older adults and found 17 significantly associated with death from any cause over a mean follow-up of 8.05 years. The reported associations replicated in a second group of 1,124 people.
The findings come from a paper in Geromedicine, quoted by the longevity site Fight Aging!. The quoted abstract gives no 2 or confidence intervals, so it does not show how large these effects were.
Why look at blood proteins?
Chronological age is a crude guide to how long someone will stay healthy. Aging researchers want better measures, and blood is easy to sample and carries proteins from throughout the body. The challenge is that screening thousands of proteins can produce chance hits, and a protein that predicts death may simply mark illness already under way.
What the team did
The discovery group came from 3, a New York study of older Ashkenazi Jewish adults, many with very long-lived parents. The researchers used 4, a standard method for estimating how a factor changes the rate of an event over time, to relate each protein to mortality.
They then compared the 17 proteins with chronic disease burden and with biological age estimates derived from blood proteins, for the whole body and for individual organs. Validation came from the 5, a long-running US government study.
The proteins
Higher levels of two proteins were associated with lower mortality and younger biological age across multiple organ systems:
ERBB1, the epidermal growth factor receptor, which helps control cell growth
ANTXR2, a cell-surface protein that anthrax toxin uses to enter cells
Higher levels of three others were associated with higher mortality and older biological age across multiple organ systems:
6, a stress-signalling protein that rises with many diseases
HE4, best known as an ovarian cancer marker
IGFBP-2, which helps regulate insulin-like growth factors
ERBB1 was also linked specifically to a younger liver. High GDF15, called by its other name, MIC-1, in the abstract, was linked to older whole-body biological age.
What this does and doesn't show
This is observational evidence and cannot establish cause. High GDF15, for example, may result from damage rather than drive it. Nor should higher plasma ERBB1 or ANTXR2 be read as a reason to boost them: plasma levels may not reflect receptor activity in tissue.
Reason, who runs Fight Aging!, adds a further caveat: it remains unclear whether such aging clocks truly measure biological age, or would still work when testing an anti-aging treatment. He still considers more performance data potentially useful.
Nothing changes for patients yet. These proteins are leads for further research, not validated tests or treatment targets.
Researchers have screened 4,265 1 proteins in 1,025 older adults and found 17 whose levels were significantly associated with death from any cause. They then asked whether those proteins also tracked chronic disease burden and proteome-based estimates of biological age, for the whole body and for individual organs. The results were reported as replicated in a separate group of 1,124 people.
The paper appears in the journal Geromedicine. This write-up relies on the abstract quoted by Reason, who runs the longevity-focused site Fight Aging!. The abstract gives no 2, confidence intervals, statistical thresholds or list of adjustment variables, so it does not show how strong any association was.
The problem
Chronological age is a crude predictor of how long someone will live or how soon their health will fail. Aging research wants measures that capture that variation, both to study mechanisms and, potentially, to judge interventions without waiting decades for deaths to accumulate.
Blood is an obvious place to look because it is easy to sample and carries proteins from tissues throughout the body. The difficulty is separating meaningful signals from noise. Testing thousands of proteins will produce some chance associations, and a protein that predicts death may be only a marker of illness already under way.
What the researchers did
The discovery cohort came from 3, a long-running study of older Ashkenazi Jewish adults at Albert Einstein College of Medicine in New York, many of whom have very long-lived parents. The researchers followed participants for a mean of 8.05 years and used Cox proportional hazards regression to relate each protein's level to the risk of death.
4 estimates how a factor changes the rate of an event over time, expressed as a hazard ratio. As an illustration, not a figure from this study, a hazard ratio of 1.5 per unit of a protein would mean a 50% higher death rate at any given moment for each unit increase. It describes a relative rate, not a person's absolute chance of dying.
The 17 proteins that passed the screen were then compared with chronic disease burden and with biological age measures derived from the proteome. Reason describes these as a consensus approach to estimating biological age. The quoted text does not explain how that consensus was built or which organs were covered.
Validation used the 5, a US National Institute on Aging study that began in 1958. Testing findings in an independent cohort matters because it helps weed out chance results and quirks specific to one population.
What they found
Higher levels of two proteins were associated with lower mortality and younger biological age across multiple organ systems:
ERBB1, also called the epidermal growth factor receptor, normally sits on cell surfaces and helps control cell growth and repair.
ANTXR2, or anthrax toxin receptor 2, is a cell-surface protein that the anthrax toxin exploits to enter cells. It also has normal roles in the body unrelated to infection.
Higher levels of three others were associated with higher mortality and older biological age across multiple organ systems:
6, or growth differentiation factor 15, is a stress-signalling protein that rises with many diseases and with age.
HE4, or human epididymis protein 4, is best known as a blood marker used in assessing ovarian cancer.
IGFBP-2, or insulin-like growth factor-binding protein 2, binds insulin-like growth factors and helps regulate their activity.
Two more specific associations stood out. Elevated MIC-1 was linked to older biological age for the organism as a whole, and ERBB1 was linked to a younger liver. MIC-1, or macrophage inhibitory cytokine-1, is another name for GDF15, a point the abstract does not make clear. GDF15 therefore appears in both the multi-organ and whole-body results.
The abstract says "these associations" replicated in BLSA, but does not specify whether that means all 17 proteins, the five named ones, or the organ-specific findings.
How far the evidence goes
This is an observational cohort study, so it cannot show that any of these proteins causes aging or protects against it. Three limitations stand out.
7. Because GDF15 rises with illness and physiological stress, high levels may reflect existing damage rather than drive it. In that case, lowering the protein might not extend life. The same question applies to the other markers. The abstract reports links with chronic disease burden, but it does not say how far disease accounts for the mortality signal.
What the plasma measure represents. ERBB1 and ANTXR2 do much of their work on cell surfaces. A level measured in plasma may not reflect how active those receptors are in tissue, so "more is better" should not be read as a case for boosting them. The direction of effect also offers no support for treatment: EGFR overactivity drives some cancers, and drugs that block it are used against them.
Clock validity. Reason's main caveat is that it remains uncertain whether such clocks truly measure biological age, or whether they would still give useful readings when an anti-aging intervention is involved. A clock built from ordinary aging patterns could move under treatment without any health gain, or miss a real benefit that works through a different pathway. There is also some circularity here: if a protein contributes to a proteomic age estimate, a link between the two is partly built in. The abstract does not say whether the authors dealt with that overlap. Even so, Reason considers further data on how these clocks perform to be potentially useful.
What changes now
Nothing changes for patients. The abstract does not describe a validated clinical test, a treatment target or evidence that altering these proteins changes outcomes. The results may help researchers prioritize markers for further study. Better tests would include formal causal analyses, such as 8, which uses inherited genetic differences to probe causation, and intervention trials that track both these proteins and clinical outcomes.
Remember
Screening 4,265 proteins yielded just 17 mortality-linked hits, roughly 0.4%, before the replication step in a second cohort.
GDF15 and MIC-1 are the same protein, so the abstract's two names describe a single signal.
A protein predicting death is not automatically a drug target; high levels may be a consequence of disease.
A child in rural northern New York has died after contracting measles, the state's first death from the disease in 30 years, Gov. Kathy Hochul announced on Monday. The death occurred in Lewis County, about 93 miles north of Syracuse.
The Associated Press report does not give the child's age, vaccination status or health history, or the size of any local outbreak.
Why coverage matters
The US stopped the domestic spread of measles in 2000 through high vaccination rates. Those rates have since fallen below 95%, the coverage needed to prevent outbreaks.
That threshold reflects how contagious measles is. As an illustration, suppose one infected person would otherwise infect 15 others. If 95% of those around them are immune, each case produces fewer than one new case on average, and the outbreak fades. At 90% immunity, each case produces about 1.5 new ones, and it grows. This protection is called 1: enough people are immune that the virus cannot keep spreading.
Federal and state counts differ
The 2 has confirmed three measles-associated deaths in the US this year. Pennsylvania alone has reported five and is investigating a sixth. With New York's case, two states account for at least six reported deaths, double the federal figure.
The article does not explain the gap or say whether the CDC's count includes this child, so the national number may be incomplete.
What New York has changed
Hochul declared a 3 in early October because of cases in neighboring states and rural parts of New York. The order lets paramedics, midwives and others give measles vaccines, and lets nurses as well as doctors order testing. The article gives no data on how many extra doses or tests have followed, so its effect is unknown.
Weighing the blame
Hochul, a Democrat, called the death "a devastating reminder of what's at stake when Washington deliberately erodes decades of progress in protecting Americans from preventable illnesses." That is a political attribution. The article offers no evidence tying specific federal actions to this death, and one case could not establish such a link.
The solid facts are the death, the 30-year gap and the shortfall in coverage. Still unknown is whether this was an isolated tragedy or a sign of wider spread in undervaccinated rural communities. The outbreak's size and the child's circumstances would help answer that.
A child in rural northern New York has died after contracting measles, the state's first death from the disease in 30 years, Gov. Kathy Hochul announced on Monday. The death occurred in Lewis County, about 93 miles (150 kilometers) north of Syracuse.
The Associated Press report is brief. It does not give the child's age, vaccination status or underlying health, the complications involved, or how many cases are linked to the local spread. Those details matter, because they determine whether this child could have been protected directly by vaccination or depended on the immunity of people nearby.
Why 95% is the number that matters
The US stopped the domestic spread of measles in 2000 by maintaining high vaccination rates. Those rates have since fallen below the 95% coverage needed to prevent outbreaks.
The threshold follows from how contagious the virus is. This is an illustration using a commonly cited estimate rather than data from the New York cases: suppose one infected person would otherwise infect 15 others.
If 95% of the people around them are immune, about 0.75 of those 15 can catch it, so on average each case produces fewer than one new case and the outbreak fades.
If 90% are immune, each case produces about 1.5 new ones, so the outbreak grows.
That is 1, the point at which enough people are immune that the virus cannot keep spreading. A few percentage points can separate a dead-end introduction from a sustained outbreak. Averages can also hide risk: coverage varies by community, so a state's overall figure can look healthy while a county or school does not.
A national count that doesn't add up
The 2 has confirmed three measles-associated deaths in the US this year, but state health departments report more. Pennsylvania alone has reported five and is investigating a possible sixth. With New York's case, that is at least six state-reported deaths from two states, double the federal number.
The article does not explain the gap, or say whether the CDC's count includes the New York child. Reporting lags or different criteria for attributing a death to measles could play a part, but that is speculation. For now, the three confirmed deaths are best read as a figure that may be incomplete, and the state tallies as reports that have not been reconciled with it.
What New York has done
Hochul declared a 3 in early October, citing measles cases in neighboring states and in rural parts of New York. The executive order made two practical changes:
More vaccinators: paramedics, midwives and others can now give measles vaccines.
More test orders: nurses, as well as doctors, can order testing.
Both changes widen access by adding staff who are already in the community, which may be especially useful in rural areas with few doctors. The article reports no data on how many extra doses or tests have followed, so whether the order has had a measurable effect is unknown. The order came about a month before this death was announced, and nothing in the report shows whether it could have changed this outcome.
The political argument
Hochul, a Democrat, called the death "a devastating reminder of what's at stake when Washington deliberately erodes decades of progress in protecting Americans from preventable illnesses." That is her attribution of blame, not a finding. The article cites no evidence linking specific federal actions to this death or to the decline in coverage, which it says has occurred "in recent years." One death cannot establish such a link in either direction.
What remains open
The firmer claims here are the death itself, the state's 30-year gap and the coverage shortfall. The open questions are the size of the Lewis County outbreak, the child's circumstances, and why state and federal death counts differ. Those answers would show whether this was an isolated tragedy or a sign of wider spread in undervaccinated rural communities.
Remember
Small coverage drops matter for measles: in a simple illustration, moving from 95% to 90% immunity turns fading spread into growth.
Pennsylvania's five reported deaths alone exceed the CDC's three confirmed nationwide, and the report does not explain the discrepancy.
Key facts remain undisclosed, including the child's age and vaccination status, so little can be concluded about individual preventability.
Malaria vaccine.9, the global vaccine alliance, and UNICEF agreed to cut the price of the 10 vaccine by about 40%, from €9.30 to €5.50 a dose, starting in early 2027. Roughly $50 million in savings through 2029 could fund full four-dose courses for up to one million more children.
Veteran homelessness. A Community Solutions analysis projects an 8.2% drop in 2026 from 2025, the largest in a decade, taking the count below 30,000. This is a projection, not a final count.
